Levetiracetam Tablet, Film Coated
Product Images NDC 0904-7124

10 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0904-7124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam, a molecule featuring a pyrrolidone ring attached to an ethyl group and an amide functional group.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to treatment with placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows about 7.4% response for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day, with an asterisk indicating statistical significance versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
Bar graph showing responder rates (≥50% reduction from baseline) in Study 2 Period A for Levetiracetam tablets. The graph compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Statistically significant differences versus placebo are indicated for both Levetiracetam doses.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
Bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients achieving a 50% or greater reduction. It shows 14.4% for placebo (N=104) and 39.4% for Levetiracetam 3000 mg/day (N=180), with a statistical significance indicator for Levetiracetam versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar graph titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients achieving response between placebo and levetiracetam groups. The placebo group (N=97) shows a 19.6% responder rate, and the levetiracetam group (N=101) shows a 44.6% responder rate, with a statistical significance indicator versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar chart comparing the responder rate for patients aged 1 month to less than 4 years with at least 50% reduction from baseline in Study 5. The chart shows two bars: one for Placebo with a responder rate of 19.6% (N=51), and one for Levetiracetam with a responder rate of 43.1% (N=58), indicating a statistically significant difference versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' comparing the percentage of patients responding to placebo versus levetiracetam. The y-axis shows the percentage of patients, with placebo response at 45.2% and levetiracetam response at 72.2%, indicating a higher responder rate for levetiracetam. A note highlights statistical significance versus placebo.*
FDA Label Image

250mg Carton Label (Image 01)

250mg Carton Label (Image 01)
Levetiracetam 250 mg film-coated tablets by Major Pharmaceuticals, packaged as unit dose with 100 tablets (10 x 10). The label includes NDC 0904-7123-61, dispensing instructions, storage conditions, and a barcode. It notes the product is for prescription use only and is made in India.*
FDA Label Image

500mg Carton Label (Image 02)

500mg Carton Label (Image 02)
Levetiracetam 500 mg film-coated tablets, USP, labeled for oral use by Major Pharmaceuticals. The unit dose packaging shows 100 tablets (10 x 10) with instructions to dispense with medication guide and store at controlled room temperature. The label includes the NDC 0904-7124-61 and cautions for pharmacist and patient usage.*
FDA Label Image

750mg Carton Label (Image 03)

750mg Carton Label (Image 03)
Levetiracetam 750 mg film-coated tablets label from Major Pharmaceuticals. The unit dose packaging contains 100 tablets (10 x 10) with directions for pharmacists to dispense with a medication guide. The label includes storage instructions, dosage guidance, and a barcode with NDC 0904-7125-61. Packaged and distributed by Major Pharmaceuticals in Indianapolis, IN.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.